ID   RDH1_HUMAN              Reviewed;         318 AA.
AC   Q92781; O00179; Q8TAI2;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1997, sequence version 1.
DT   10-MAY-2017, entry version 158.
DE   RecName: Full=11-cis retinol dehydrogenase;
DE            Short=11-cis RDH;
DE            Short=11-cis RoDH;
DE            EC=1.1.1.315;
DE   AltName: Full=9-cis retinol dehydrogenase;
DE            Short=9cRDH;
DE   AltName: Full=Retinol dehydrogenase 5;
DE   AltName: Full=Short chain dehydrogenase/reductase family 9C member 5;
DE   Flags: Precursor;
GN   Name=RDH5; Synonyms=HSD17B9, RDH1, SDR9C5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8884265; DOI=10.1006/geno.1996.0487;
RA   Simon A., Lagercrantz J., Bajalica-Lagercrantz S., Eriksson U.;
RT   "Primary structure of human 11-cis retinol dehydrogenase and
RT   organization and chromosomal localization of the corresponding gene.";
RL   Genomics 36:424-430(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, PATHWAY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, TISSUE SPECIFICITY, AND VARIANT GLY-70.
RC   TISSUE=Mammary gland;
RX   PubMed=9115228; DOI=10.1074/jbc.272.18.11744;
RA   Mertz J.R., Shang E., Piantedosi R., Wei S., Wolgemuth D.J.,
RA   Blaner W.S.;
RT   "Identification and characterization of a stereospecific human enzyme
RT   that catalyzes 9-cis-retinol oxidation. A possible role in 9-cis-
RT   retinoic acid formation.";
RL   J. Biol. Chem. 272:11744-11749(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RA   Gu S., Jablonka S., Gal A.;
RT   "Retinol dehydrogenase: complete genomic sequence and its relationship
RT   to retinitis pigmentosa.";
RL   Submitted (DEC-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=10588954;
RA   Gamble M.V., Shang E., Zott R.P., Mertz J.R., Wolgemuth D.J.,
RA   Blaner W.S.;
RT   "Biochemical properties, tissue expression, and gene structure of a
RT   short chain dehydrogenase/reductase able to catalyze cis-retinol
RT   oxidation.";
RL   J. Lipid Res. 40:2279-2292(1999).
RN   [6]
RP   SUBUNIT, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANTS FALBI
RP   SER-35; PHE-73; ILE-105; ASN-128; TRP-157; TRP-238; GLY-264; HIS-280;
RP   PRO-294 AND 309-GLU-VAL-310 DELINS.
RX   PubMed=11675386; DOI=10.1074/jbc.M107337200;
RA   Liden M., Romert A., Tryggvason K., Persson B., Eriksson U.;
RT   "Biochemical defects in 11-cis-retinol dehydrogenase mutants
RT   associated with fundus albipunctatus.";
RL   J. Biol. Chem. 276:49251-49257(2001).
RN   [7]
RP   VARIANTS FALBI TRP-238; HIS-280 AND PRO-294.
RX   PubMed=10617778;
RA   Gonzalez-Fernandez F., Kurz D., Bao Y., Newman S., Conway B.P.,
RA   Young J.E., Han D.P., Khani S.C.;
RT   "11-cis retinol dehydrogenase mutations as a major cause of the
RT   congenital night-blindness disorder known as fundus albipunctatus.";
RL   Mol. Vis. 5:41-41(1999).
RN   [8]
RP   VARIANTS FALBI PHE-73 AND TRP-238, AND VARIANT VAL-33.
RX   PubMed=10369264; DOI=10.1038/9707;
RA   Yamamoto H., Simon A., Eriksson U., Harris E., Berson E.L.,
RA   Dryja T.P.;
RT   "Mutations in the gene encoding 11-cis retinol dehydrogenase cause
RT   delayed dark adaptation and fundus albipunctatus.";
RL   Nat. Genet. 22:188-191(1999).
RN   [9]
RP   VARIANTS FALBI GLY-177 AND HIS-280.
RX   PubMed=11078852; DOI=10.1016/S0002-9394(00)00765-0;
RA   Kuroiwa S., Kikuchi T., Yoshimura N.;
RT   "A novel compound heterozygous mutation in the RDH5 gene in a patient
RT   with fundus albipunctatus.";
RL   Am. J. Ophthalmol. 130:672-675(2000).
RN   [10]
RP   VARIANTS FALBI SER-35; ARG-107; MET-132; HIS-280; HIS-281 AND
RP   309-GLU-VAL-310 DELINS.
RX   PubMed=11053295;
RA   Nakamura M., Hotta Y., Tanikawa A., Terasaki H., Miyake Y.;
RT   "A high association with cone dystrophy in Fundus albipunctatus caused
RT   by mutations of the RDH5 gene.";
RL   Invest. Ophthalmol. Vis. Sci. 41:3925-3932(2000).
RN   [11]
RP   VARIANT FALBI TRP-267.
RX   PubMed=11470705; DOI=10.1016/S0161-6420(01)00640-6;
RA   Driessen C.A., Janssen B.P., Winkens H.J., Kuhlmann L.D.,
RA   Van Vugt A.H., Pinckers A.J., Deutman A.F., Janssen J.J.;
RT   "Null mutation in the human 11-cis retinol dehydrogenase gene
RT   associated with fundus albipunctatus.";
RL   Ophthalmology 108:1479-1484(2001).
RN   [12]
RP   VARIANT FALBI ARG-107.
RX   PubMed=12788147; DOI=10.1016/S0002-9394(02)02290-0;
RA   Hotta K., Nakamura M., Kondo M., Ito S., Terasaki H., Miyake Y.,
RA   Hida T.;
RT   "Macular dystrophy in a Japanese family with fundus albipunctatus.";
RL   Am. J. Ophthalmol. 135:917-919(2003).
RN   [13]
RP   VARIANT FALBI PHE-164.
RX   PubMed=12967826; DOI=10.1016/S0002-9394(03)00332-5;
RA   Yamamoto H., Yakushijin K., Kusuhara S., Escano M.F., Nagai A.,
RA   Negi A.;
RT   "A novel RDH5 gene mutation in a patient with fundus albipunctatus
RT   presenting with macular atrophy and fading white dots.";
RL   Am. J. Ophthalmol. 136:572-574(2003).
RN   [14]
RP   VARIANT FALBI PHE-175.
RX   PubMed=25820994; DOI=10.1007/s13353-015-0281-x;
RA   Skorczyk-Werner A., Pawlowski P., Michalczuk M., Warowicka A.,
RA   Wawrocka A., Wicher K., Bakunowicz-Lazarczyk A., Krawczynski M.R.;
RT   "Fundus albipunctatus: review of the literature and report of a novel
RT   RDH5 gene mutation affecting the invariant tyrosine (p.Tyr175Phe).";
RL   J. Appl. Genet. 56:317-327(2015).
CC   -!- FUNCTION: Stereospecific 11-cis retinol dehydrogenase, which
CC       catalyzes the final step in the biosynthesis of 11-cis
CC       retinaldehyde, the universal chromophore of visual pigments. Also
CC       able to oxidize 9-cis-retinol and 13-cis-retinol, but not all-
CC       trans-retinol. Active in the presence of NAD as cofactor but not
CC       in the presence of NADP. {ECO:0000269|PubMed:10588954,
CC       ECO:0000269|PubMed:9115228}.
CC   -!- CATALYTIC ACTIVITY: 11-cis-retinol-[retinal-binding-protein] +
CC       NAD(+) = 11-cis-retinal-[retinol-binding-protein] + NADH.
CC       {ECO:0000269|PubMed:10588954, ECO:0000269|PubMed:9115228}.
CC   -!- ENZYME REGULATION: Inhibited by 9-cis-, 13-cis- and all-trans-
CC       retinoic acids, with the most potent inhibitor being 13-cis-
CC       retinoic acid. Weakly inhibited by oleic acid.
CC       {ECO:0000269|PubMed:10588954}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 7.5-8.0 for 9-cis retinol dehydrogenase activity.
CC         {ECO:0000269|PubMed:9115228};
CC   -!- PATHWAY: Cofactor metabolism; retinol metabolism.
CC       {ECO:0000269|PubMed:9115228}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:11675386}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:11675386};
CC       Peripheral membrane protein {ECO:0000269|PubMed:11675386}.
CC       Endoplasmic reticulum lumen {ECO:0000269|PubMed:11675386}.
CC   -!- TISSUE SPECIFICITY: Abundant in the retinal pigment epithelium.
CC       Expressed at high levels in mammary tissue, kidney and testis, and
CC       at lower levels in liver, heart, adrenal gland, lung, pancreas and
CC       skeletal muscle. {ECO:0000269|PubMed:9115228}.
CC   -!- DISEASE: Fundus albipunctatus (FALBI) [MIM:136880]: A form of
CC       fleck retina disease characterized by discrete uniform white dots
CC       over the entire fundus with greatest density in the mid-periphery
CC       and no macular involvement. Night blindness occurs. Inheritance
CC       can be autosomal dominant or autosomal recessive.
CC       {ECO:0000269|PubMed:10369264, ECO:0000269|PubMed:10617778,
CC       ECO:0000269|PubMed:11053295, ECO:0000269|PubMed:11078852,
CC       ECO:0000269|PubMed:11470705, ECO:0000269|PubMed:11675386,
CC       ECO:0000269|PubMed:12788147, ECO:0000269|PubMed:12967826,
CC       ECO:0000269|PubMed:25820994}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the short-chain dehydrogenases/reductases
CC       (SDR) family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Mutations of the RDH5 gene; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="http://www.retina-international.org/files/sci-news/rdh5mut.htm";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U43559; AAC50725.1; -; mRNA.
DR   EMBL; U89717; AAB93668.1; -; mRNA.
DR   EMBL; AF037062; AAC09250.1; -; Genomic_DNA.
DR   EMBL; BC028298; AAH28298.1; -; mRNA.
DR   CCDS; CCDS31829.1; -.
DR   RefSeq; NP_001186700.1; NM_001199771.1.
DR   RefSeq; NP_002896.2; NM_002905.3.
DR   UniGene; Hs.600940; -.
DR   ProteinModelPortal; Q92781; -.
DR   SMR; Q92781; -.
DR   BioGrid; 111892; 7.
DR   IntAct; Q92781; 1.
DR   STRING; 9606.ENSP00000257895; -.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB00162; Vitamin A.
DR   SwissLipids; SLP:000000797; -.
DR   iPTMnet; Q92781; -.
DR   PhosphoSitePlus; Q92781; -.
DR   BioMuta; RDH5; -.
DR   DMDM; 2492753; -.
DR   PaxDb; Q92781; -.
DR   PeptideAtlas; Q92781; -.
DR   PRIDE; Q92781; -.
DR   DNASU; 5959; -.
DR   Ensembl; ENST00000257895; ENSP00000257895; ENSG00000135437.
DR   Ensembl; ENST00000548082; ENSP00000447128; ENSG00000135437.
DR   GeneID; 5959; -.
DR   KEGG; hsa:5959; -.
DR   UCSC; uc001shk.4; human.
DR   CTD; 5959; -.
DR   DisGeNET; 5959; -.
DR   GeneCards; RDH5; -.
DR   HGNC; HGNC:9940; RDH5.
DR   HPA; HPA063345; -.
DR   MalaCards; RDH5; -.
DR   MIM; 136880; phenotype.
DR   MIM; 601617; gene.
DR   neXtProt; NX_Q92781; -.
DR   OpenTargets; ENSG00000135437; -.
DR   Orphanet; 227796; Fundus albipunctatus.
DR   Orphanet; 52427; Retinitis punctata albescens.
DR   PharmGKB; PA34308; -.
DR   eggNOG; KOG1610; Eukaryota.
DR   eggNOG; ENOG410Y7FK; LUCA.
DR   GeneTree; ENSGT00870000136397; -.
DR   HOVERGEN; HBG005482; -.
DR   InParanoid; Q92781; -.
DR   KO; K00061; -.
DR   OMA; TLQACWA; -.
DR   OrthoDB; EOG091G0LMI; -.
DR   PhylomeDB; Q92781; -.
DR   TreeFam; TF325617; -.
DR   BioCyc; MetaCyc:HS06003-MONOMER; -.
DR   BRENDA; 1.1.1.300; 2681.
DR   BRENDA; 1.1.1.315; 2681.
DR   Reactome; R-HSA-2453902; The canonical retinoid cycle in rods (twilight vision).
DR   Reactome; R-HSA-5365859; RA biosynthesis pathway.
DR   UniPathway; UPA00912; -.
DR   ChiTaRS; RDH5; human.
DR   GeneWiki; RDH5; -.
DR   GenomeRNAi; 5959; -.
DR   PRO; PR:Q92781; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000135437; -.
DR   CleanEx; HS_RDH5; -.
DR   ExpressionAtlas; Q92781; baseline and differential.
DR   Genevisible; Q92781; HS.
DR   GO; GO:0044297; C:cell body; IEA:Ensembl.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; IEA:UniProtKB-SubCell.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0004745; F:retinol dehydrogenase activity; TAS:Reactome.
DR   GO; GO:0050896; P:response to stimulus; IEA:UniProtKB-KW.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0042572; P:retinol metabolic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0007601; P:visual perception; TAS:ProtInc.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR032968; RDH5.
DR   InterPro; IPR002347; SDR_fam.
DR   PANTHER; PTHR43313:SF5; PTHR43313:SF5; 1.
DR   Pfam; PF00106; adh_short; 1.
DR   PRINTS; PR00081; GDHRDH.
DR   PRINTS; PR00080; SDRFAMILY.
DR   SUPFAM; SSF51735; SSF51735; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Disease mutation; Endoplasmic reticulum;
KW   Glycoprotein; Membrane; NAD; Oxidoreductase; Polymorphism;
KW   Reference proteome; Sensory transduction; Signal; Vision.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24    318       11-cis retinol dehydrogenase.
FT                                /FTId=PRO_0000054758.
FT   NP_BIND      32     56       NADP. {ECO:0000250}.
FT   ACT_SITE    175    175       Proton acceptor. {ECO:0000250}.
FT   BINDING     163    163       Substrate. {ECO:0000250}.
FT   CARBOHYD    160    160       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VARIANT      21     21       R -> Q (in dbSNP:rs3138143).
FT                                /FTId=VAR_052321.
FT   VARIANT      33     33       I -> V (in dbSNP:rs62638195).
FT                                {ECO:0000269|PubMed:10369264}.
FT                                /FTId=VAR_009272.
FT   VARIANT      35     35       G -> S (in FALBI; decreased stability;
FT                                dbSNP:rs759359491).
FT                                {ECO:0000269|PubMed:11053295,
FT                                ECO:0000269|PubMed:11675386}.
FT                                /FTId=VAR_016814.
FT   VARIANT      70     70       R -> G (in dbSNP:rs1058635).
FT                                {ECO:0000269|PubMed:9115228}.
FT                                /FTId=VAR_052322.
FT   VARIANT      73     73       S -> F (in FALBI; decreased stability;
FT                                loss of enzymatic activity; accumulates
FT                                in the perinuclear region;
FT                                dbSNP:rs62638185).
FT                                {ECO:0000269|PubMed:10369264,
FT                                ECO:0000269|PubMed:11675386}.
FT                                /FTId=VAR_009273.
FT   VARIANT     105    105       L -> I (in FALBI; decreased stability).
FT                                {ECO:0000269|PubMed:11675386}.
FT                                /FTId=VAR_068716.
FT   VARIANT     107    107       G -> R (in FALBI; associated with macular
FT                                dystrophy). {ECO:0000269|PubMed:11053295,
FT                                ECO:0000269|PubMed:12788147}.
FT                                /FTId=VAR_016815.
FT   VARIANT     128    128       D -> N (in FALBI; decreased stability;
FT                                dbSNP:rs377029071).
FT                                {ECO:0000269|PubMed:11675386}.
FT                                /FTId=VAR_068717.
FT   VARIANT     132    132       V -> M (in FALBI; dbSNP:rs62638187).
FT                                {ECO:0000269|PubMed:11053295}.
FT                                /FTId=VAR_016816.
FT   VARIANT     157    157       R -> W (in FALBI; decreased stability;
FT                                dbSNP:rs104894374).
FT                                {ECO:0000269|PubMed:11675386}.
FT                                /FTId=VAR_068718.
FT   VARIANT     164    164       V -> F (in FALBI).
FT                                {ECO:0000269|PubMed:12967826}.
FT                                /FTId=VAR_016817.
FT   VARIANT     175    175       Y -> F (in FALBI; dbSNP:rs758411232).
FT                                {ECO:0000269|PubMed:25820994}.
FT                                /FTId=VAR_075309.
FT   VARIANT     177    177       V -> G (in FALBI; dbSNP:rs104894373).
FT                                {ECO:0000269|PubMed:11078852}.
FT                                /FTId=VAR_016818.
FT   VARIANT     238    238       G -> W (in FALBI; decreased stability;
FT                                loss of enzymatic activity; accumulates
FT                                in the perinuclear region;
FT                                dbSNP:rs62638191).
FT                                {ECO:0000269|PubMed:10369264,
FT                                ECO:0000269|PubMed:10617778,
FT                                ECO:0000269|PubMed:11675386}.
FT                                /FTId=VAR_009274.
FT   VARIANT     264    264       V -> G (in FALBI; decreased stability).
FT                                {ECO:0000269|PubMed:11675386}.
FT                                /FTId=VAR_068719.
FT   VARIANT     267    267       C -> W (in FALBI).
FT                                {ECO:0000269|PubMed:11470705}.
FT                                /FTId=VAR_016819.
FT   VARIANT     280    280       R -> H (in FALBI; decreased stability;
FT                                loss of enzymatic activity;
FT                                dbSNP:rs62638193).
FT                                {ECO:0000269|PubMed:10617778,
FT                                ECO:0000269|PubMed:11053295,
FT                                ECO:0000269|PubMed:11078852,
FT                                ECO:0000269|PubMed:11675386}.
FT                                /FTId=VAR_016820.
FT   VARIANT     281    281       Y -> H (in FALBI; dbSNP:rs62638194).
FT                                {ECO:0000269|PubMed:11053295}.
FT                                /FTId=VAR_016821.
FT   VARIANT     294    294       A -> P (in FALBI; associated with H-280;
FT                                no effect on enzymatic activity;
FT                                accumulates in the perinuclear region;
FT                                dbSNP:rs111033593).
FT                                {ECO:0000269|PubMed:10617778,
FT                                ECO:0000269|PubMed:11675386}.
FT                                /FTId=VAR_016822.
FT   VARIANT     310    310       L -> EV (in FALBI; loss of enzymatic
FT                                activity; accumulates in the perinuclear
FT                                region).
FT                                /FTId=VAR_016823.
FT   CONFLICT     30     30       F -> L (in Ref. 4; AAH28298).
FT                                {ECO:0000305}.
FT   CONFLICT     51     52       RG -> KS (in Ref. 2; AAB93668).
FT                                {ECO:0000305}.
FT   CONFLICT     75     77       RLH -> GFN (in Ref. 2; AAB93668).
FT                                {ECO:0000305}.
FT   CONFLICT     89     89       V -> F (in Ref. 2; AAB93668).
FT                                {ECO:0000305}.
FT   CONFLICT    200    200       V -> E (in Ref. 2; AAB93668).
FT                                {ECO:0000305}.
SQ   SEQUENCE   318 AA;  34979 MW;  2CE24343F2EEA4B7 CRC64;
     MWLPLLLGAL LWAVLWLLRD RQSLPASNAF VFITGCDSGF GRLLALQLDQ RGFRVLASCL
     TPSGAEDLQR VASSRLHTTL LDITDPQSVQ QAAKWVEMHV KEAGLFGLVN NAGVAGIIGP
     TPWLTRDDFQ RVLNVNTMGP IGVTLALLPL LQQARGRVIN ITSVLGRLAA NGGGYCVSKF
     GLEAFSDSLR RDVAHFGIRV SIVEPGFFRT PVTNLESLEK TLQACWARLP PATQAHYGGA
     FLTKYLKMQQ RIMNLICDPD LTKVSRCLEH ALTARHPRTR YSPGWDAKLL WLPASYLPAS
     LVDAVLTWVL PKPAQAVY
//
